Insider Buying: Braveheart Bio (NASDAQ:BRVE) Director Acquires $1,499,994.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Christopher Viehbacher acquired 83,333 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,499,994.00. Following the completion of the acquisition, the director directly owned 609,519 shares in the company, valued at $10,971,342. The trade was a 15.84% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Braveheart Bio Stock Performance

NASDAQ BRVE traded up $0.20 during trading hours on Friday, reaching $30.00. 565,846 shares of the stock traded hands. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.